EUVIMEDEUVIMED entdecken
Systematische Übersicht

The utility of artificial intelligence in gastrointestinal oncology: A systematic review of randomized controlled trials

Der Nutzen künstlicher Intelligenz in der gastrointestinalen Onkologie: systematische Übersicht randomisierter kontrollierter Studien

Luke E Sorensen iD, Vanessa A Moore iD, Jared L Gregston, Joseph D Spear, C Asa Candler, Bibi Maryam, Shari Clifton, Katie Keyser, Anh B Lam iD, Ryan D Nipp iD

Cancer · 15.09.2025 · 131 (18)

DOI: 10.1002/cncr.70043 ↗

Auf einen Blick

Die Übersicht zeigt einen starken Anstieg von RCTs zu KI in der gastrointestinalen Onkologie. Die meisten Studien untersuchten die Detektion von Läsionen oder Tumoren mittels Endoskopie oder Ultraschall.

Fragestellung

Wie nützlich ist KI in randomisierten kontrollierten Studien zur Versorgung gastrointestinaler Malignome?

Methode

Systematische Übersicht von RCTs; Datenbanken: MEDLINE, Embase und CINAHL Ultimate.

Ergebnisse

27 RCTs mit 29.895 Patient:innen. 25 RCTs (93 %) hatten als primären Endpunkt die Detektion von Läsionen/Krebs im Gastrointestinaltrakt; 22 von 27 Studien (81 %) erreichten ihren primären Endpunkt signifikant.

Schlussfolgerung der Autor:innen

Die Autor:innen beobachteten einen jüngsten Anstieg der Zahl von RCTs zu KI in der gastrointestinalen Onkologie und identifizierten spezifische Einsatzbereiche.

Kernaussagen

  • 27 RCTs mit 29.895 Patient:innen
  • 25 RCTs mit Detektionsendpunkt
  • 22 von 27 Studien erreichten den primären Endpunkt signifikant

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer, online erschienen am 06.09.2025. Verfasst von Luke E Sorensen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Gastrointestinal Neoplasms, Medical Oncology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the field of gastrointestinal oncology, the development of novel artificial intelligence (AI) processes may help with multiple aspects of cancer care delivery. However, a comprehensive understanding of the current utility of AI in gastrointestinal oncology is lacking. The authors conducted searches in the following databases: MEDLINE (Ovid), Embase (Ovid), and CINAHL (Cumulative Index of Nursing and Allied Health) Ultimate (EBSCO). The analysis focused on publication trends and outcomes of randomized controlled trials (RCTs) that used AI to manage gastrointestinal malignancies. From our initial search retrieval of 3730 studies, 27 RCTs (with a total of 29,895 patients) were identified that met inclusion criteria. The first RCT was published in 2019, followed by five in 2020, four in 2021, six in 2022, and 11 in 2023. Colorectal malignancies comprised the majority of the literature (23 of 27 studies; 85%), with other studies focused on gastric cancer (three of 27 studies; 11%) and hepatocellular carcinoma (one of 27 studies; 4%). Of the included RCTs, 25 (93%) had a primary outcome focused on lesion/cancer detection throughout the gastrointestinal tract using endoscopy or ultrasound, with others focused on algorithmic‐based AI assistance with postoperative pain management or histologic diagnosis. Overall, 22 of 27 studies (81%) met their primary end point with a statistically significant result. In this systematic review, the authors observed a recent increase in the number of RCTs focused on AI within the field of gastrointestinal oncology and identified specific areas in which AI is being used. Findings from this work should help to inform further investigations to develop and test innovative AI uses, enhance care delivery, and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceGastrointestinal NeoplasmsMedical OncologyHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

artificial intelligencecolorectal neoplasmsendoscopygastrointestinal neoplasmshepatocellular carcinomamachine learningrandomized controlled trialssystematic review

Autor:innen und Institutionen

  • Department of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
  • College of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
  • Bird Health Sciences Library, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
  • Section of Hematology and Oncology, Department of Medicine, University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.

ORCID-Profile: Luke E Sorensen, Vanessa A Moore, Anh B Lam, Ryan D Nipp

Zitieren

APA

Sorensen, L. E., Moore, V. A., Gregston, J. L., Spear, J. D., Candler, C. A., Maryam, B., Clifton, S., Keyser, K., Lam, A. B., & Nipp, R. D. (2025). The utility of artificial intelligence in gastrointestinal oncology: A systematic review of randomized controlled trials. Cancer, 131(18). https://doi.org/10.1002/cncr.70043

Vancouver

Sorensen LE, Moore VA, Gregston JL, Spear JD, Candler CA, Maryam B, et al. The utility of artificial intelligence in gastrointestinal oncology: A systematic review of randomized controlled trials. Cancer. 2025;131(18). doi:10.1002/cncr.70043

BibTeX
@article{Sorensen2025,
  author = {Sorensen, Luke E and Moore, Vanessa A and Gregston, Jared L and Spear, Joseph D and Candler, C Asa and Maryam, Bibi and Clifton, Shari and Keyser, Katie and Lam, Anh B and Nipp, Ryan D},
  title = {The utility of artificial intelligence in gastrointestinal oncology: A systematic review of randomized controlled trials},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {18},
  doi = {10.1002/cncr.70043}
}
Kostenlos starten →